

1 **SUPPLEMENTAL INFORMATION**

2  
3 **Biochemical Characterization of Essential Cell Division Proteins FtsX and FtsE**  
4 **That Mediate Peptidoglycan Hydrolysis by PcsB in *Streptococcus pneumoniae***

5  
6 Ruchika Bajaj<sup>1</sup>, Kevin E. Bruce<sup>2</sup>, Amy L. Davidson<sup>1‡</sup>, Britta E. Rued<sup>2</sup>, Cynthia V.  
7 Stauffacher<sup>1</sup>, and Malcolm E. Winkler<sup>\*2</sup>

8  
9 <sup>1</sup>Department of Biological Sciences, Purdue University, West Lafayette, IN 47907 and

10 <sup>2</sup>Department of Biology, Indiana University Bloomington, Bloomington, IN 47405, USA

11  
12 Running title: Reconstitution of Pneumococcal FtsX in Nanodiscs

13  
14 **Supplemental Tables: S1-S3**

15 **Supplemental Figure Legends: S1-S5**

16  
17  
18 **Corresponding author:**

19 Malcolm E. Winkler

20 Department of Biology

21 Indiana University Bloomington

22 1001 E. 3<sup>rd</sup> St.

23 Bloomington, IN 47405 USA

24 Phone: 812-856-1318

25 E-mail: [winklerm@indiana.edu](mailto:winklerm@indiana.edu)

**Table S1.** Bacterial strains and primers used in this study

Strain number	<i>E. coli</i> strain	Plasmid <sup>a</sup>	Antibiotic resistance marker <sup>b</sup>	Construction <sup>c</sup>	Description <sup>a</sup>	Reference
IU6892	BL21AI	pETCT- <i>ftsX</i> -GFP-His <sub>8</sub>	Kan	<i>ftsX</i> cloned into pET-CT-GFP-HIS-LIC with <i>NdeI</i> and <i>XhoI</i>	C-terminal GFP and His <sub>8</sub> tagged FtsX	This study
Primer		Sequence (5'-3'; RE sites in <b>bold</b> ) <sup>d</sup>				
KB103		CTTTAAGAAGGAGATATAC <b>CATATG</b> TGCATTGCCATTGAAAATGGCCGTG				
KB100		CAGAAAATATAAATTTT <b>CCTCGAGA</b> ATCTTCAAGAATCGGCGCATGGA				
IU6884	BL21AI	pEVL4-His <sub>6</sub> -GFP- <i>ftsX</i>	Kan	<i>ftsX</i> cloned into pEV-L4 with <i>KpnI</i> and <i>EcoRI</i>	N-terminal GFP and His <sub>6</sub> tagged FtsX	This study
Primer		Sequence (5'-3'; RE sites in <b>bold</b> )				
KB104		GATGAACTCTACCGAG <b>GTACCG</b> AACCTGTACTTCCAATCCTCATTGCCATT				
KB102		ACGTGCCAC <b>GAATTC</b> CCTAAATCTTCAAGAATCGGCG				
IU10693	BL21DE3	pETCT- <i>ftsX</i> -GFP-His <sub>8</sub>	Kan	See IU6892 above	C-terminal GFP and His <sub>8</sub> tagged FtsX	This study
IU6942	BL21DE3	pET22b- <i>ftsX</i> -His <sub>6</sub>	Amp	<i>ftsX</i> cloned into pET22b with <i>NdeI</i> and <i>NotI</i>	C-terminal His <sub>6</sub> tagged FtsX	This study
Primer		Sequence (5'-3'; RE sites in <b>bold</b> )				
KB119		CGGTAG <b>CATATG</b> TGCATTGCCATTGAAAATGGCCGTG				
KB120		AGT <b>GCGGCCGCA</b> ATCTTCAAGAATCGGCGCATGG				
IU4340	BL21DE3	pET22b- <i>ftsE</i> -His <sub>6</sub>	Amp	<i>ftsE</i> cloned into pET22b with <i>NdeI</i> and <i>NotI</i>	C-terminal His <sub>6</sub> tagged FtsE	This study
Primer		Sequence (5'-3'; RE sites in <b>bold</b> )				
CS132		ATAC <b>CATATG</b> TCAATTATTGAAATGAGAGATGTCGTT				
CS133		AGT <b>GCGGCCGCA</b> TATCGTATCCATACTCTCCTTTTGATTC				
IU6917	BL21DE3	pACYC-Duet- <i>ftsE</i>	Chl	<i>ftsE</i> cloned into pACYC Duet with <i>NdeI</i> and <i>XhoI</i>	Untagged FtsE	This study
Primer		Sequence (5'-3'; RE sites in <b>bold</b> )				
KB96		CGGTAG <b>CATATG</b> TCAATTATTGAAATGAGAGATGTC				
KB118		CCG <b>CCTCGAG</b> CTAATCATCGTATCCATACTCTCC				
IU6454	BL21DE3	pACYC-Duet- <i>ftsX</i>	Chl	<i>ftsX</i> cloned into pACYC Duet with <i>NdeI</i> and <i>KpnI</i>	Untagged FtsX	This study

Primer		Sequence (5'-3'; RE sites in <b>bold</b> )				
CS241		CCGG <b>CATATG</b> ATTAGTAGATTTTTTCGCCATTTATTTG				
CS242		CCGGGGT <b>ACCAATCTTCAAGAATCGGCGCAT</b>				
IU10588	BL21DE3	pET22b- <i>ftsE</i> -His <sub>6</sub> pACYC-Duet- <i>ftsX</i>	Amp, Chl	<i>ftsE</i> cloned into pET22b with <i>NdeI</i> and <i>NotI</i> <i>ftsX</i> cloned in pACYC Duet with <i>NdeI</i> and <i>KpnI</i>	Co-expressed C-terminal His <sub>6</sub> tagged FtsE and untagged FtsX	This study
Primer		Sequence (5'-3'; RE sites in <b>bold</b> )				
CS132		ATAC <b>CATATG</b> TCAATTATTGAAATGAGAGATGTCGTT				
CS133		AGT <b>GCGGCCGC</b> CATCATCGTATCCATACTCTCCTTTTGATTC				
CS241		CCGG <b>CATATG</b> ATTAGTAGATTTTTTCGCCATTTATTTG				
CS242		CCGGGGT <b>ACCAATCTTCAAGAATCGGCGCAT</b>				
IU10589	BL21DE3	pET22b- <i>ftsX</i> -His <sub>6</sub> pACYC-Duet- <i>ftsE</i>	Amp, Chl	<i>ftsX</i> cloned into pET22b with <i>NdeI</i> and <i>NotI</i> <i>ftsE</i> cloned into pACYC Duet with <i>NdeI</i> and <i>XhoI</i>	Co-expressed C-terminal His <sub>6</sub> tagged FtsX and untagged FtsE	This study
Primer		Sequence (5'-3'; RE sites in <b>bold</b> )				
KB119		CGGTAG <b>CATATG</b> TCAATTATTGAAATGGCCGTCG				
KB120		AGT <b>GCGGCCGC</b> CAATCTTCAAGAATCGGCGCATGG				
KB96		CGGTAG <b>CATATG</b> TCAATTATTGAAATGAGAGATGTC				
KB118		CCG <b>CTCGAG</b> CTAATCATCGTATCCATACTCTCC				
IU1614	BL21DE3	pET22b- <i>pcsB</i> <sup>AN27</sup> -His <sub>6</sub>	Amp, Chl	<i>pcsB</i> <sup>AN27</sup> cloned into pET22b with <i>NdeI</i> and <i>NotI</i>	C-terminal His <sub>6</sub> tagged PcsB with first 27 residues deleted	Barendt <i>et al.</i> , 2009
Primer		Sequence (5'-3'; RE sites in <b>bold</b> )				
WN119		CTCGAG <b>GCGGCCGC</b> ATCTGCATAAATATATGTAACAAAACC				
WN117		<b>CATATG</b> GAAACGACTGATGACAAAATTGCTG				
IU4561	BL21AI	pET22b- <i>pcsB</i> <sup>28-259</sup> (CC)-His <sub>6</sub>	Amp	<i>pcsB</i> <sup>28-259</sup> (CC) cloned into pET22b with <i>NdeI</i> and <i>NotI</i>	C-terminal His <sub>6</sub> tagged PcsB CC domain	Sham <i>et al.</i> , 2011
Primer		Sequence (5'-3'; RE sites in <b>bold</b> )				
WN117		<b>CATATG</b> GAAACGACTGATGACAAAATTGCTG				
KG002		ACGGAATAG <b>GCGGCCGC</b> AGCTGTAAAGTTAGTGTGTTGCTGAAGCA				
IU1791	BL21DE3	pET22b- <i>pcsB</i> <sup>271-392</sup> (CHAP)-	Amp, Chl	<i>pcsB</i> <sup>271-392</sup> (CHAP) cloned into pET22b	C-terminal His <sub>6</sub> tagged PcsB CHAP	Sham <i>et al.</i> , 2011

		His <sub>6</sub>		with <i>Nde</i> I and <i>Not</i> I	domain	
	Primer	Sequence (5'-3'; RE sites in <b>bold</b> )				
	SC001	GGAATT <b>CCATATGG</b> TCCGTGCAAAAGTTCGTCCAACAT				
	WN119	CTCGAG <b>GCGGCCGC</b> ATCTGCATAAATATATGTAACAAAACC				

28 <sup>a</sup>His<sub>8</sub> and His<sub>6</sub> tags are abbreviated as “His” in the text.

29 <sup>b</sup>Antibiotic resistance markers: Amp, ampicillin; Kan, kanamycin; Chl,  
30 chloramphenicol.

31 <sup>c</sup>See Materials and Methods for additional information about plasmid constructs.

32 <sup>d</sup>RE site, restriction enzyme cleavage site built into primers to allow cloning of  
33 amplicons synthesized by high-fidelity PCR.

34  
35

**Table S2.** Detergent screening for optimal extraction of FtsX-GFP-His from membranes<sup>a</sup>

Detergent <sup>b</sup>	Fluorescence intensity recovered in detergent-extracted membrane supernates (RFU) <sup>c</sup>
None	899
1% DDM	<b>2,902</b>
2% DDM	<b>3,231</b>
1% OG	2,441
2% OG	2,038
1% Fos12	2,539
2% Fos12	3,470
1% Sodium Cholate	2,671
2% Sodium Cholate	984
1% LDAO	<b>3,539</b>
2% LDAO	<b>3,051</b>
1% Anergent	<b>3,412</b>
2% Anergent	<b>2,742</b>
1% CHAPS	2,181
2% CHAPS	1,718

36 <sup>a</sup>Strain IU6892 (BL21AI/pETCT-ftsX-GFP-His) was grown and induced as described  
37 in Materials and Methods.

38 <sup>b</sup>FtsX-GFP-His was extracted from membranes with the concentrations of detergents  
39 shown as described in Materials and Methods. Abbreviations: DDM = n-dodecyl- $\beta$ -D-  
40 maltoside; OG = n-octyl- $\beta$ -D-glucoside; Fos12 = foscholine-12 = n-  
41 dodecylphosphocholine; LDAO = n-dodecyl-N, N-dimethylamine oxide, CHAPS = [3-[(3-  
42 cholamidopropyl)-dimethylammonio]-1-propane sulfonate] Detergents were obtained  
43 from Anatrace, Inc.

44 <sup>c</sup>RFU = random fluorescence unit. Most effective detergents for FtsX-GFP-His  
45 solubilization from membranes are emboldened. DDM was the most effective and  
46 economical detergent and was incorporated in the purification procedures in Materials  
47 and Methods.

48 **Table S3.** Optimization of FtsX-GFP-His expression by varying IPTG concentrations<sup>a</sup>

[IPTG] (mM)	Fluorescence intensity (RFU) <sup>b</sup>		
	Cell lysates	Membrane resuspension	DDM-extracted membrane supernate <sup>c</sup>
0	434	140	115
0.1	7,240	7,640	5,503
0.5	10,936	12,651	11,646
<b>1.0</b>	<b>8,074</b>	<b>13,216</b>	<b>13,816</b>

49 <sup>a</sup>Strain IU10693 (BL21DE3/pETCT-ftsX-GFP-His) was grown and induced as

50 described in Materials and Methods.

51 <sup>b</sup>RFU = random fluorescence unit.

52 <sup>c</sup>FtsX-GFP-His was extracted from membranes with 1% (wt/vol) DDM as described

53 in Materials and Methods.

54 **SUPPLEMENTAL FIGURE LEGENDS**

55 **Fig. S1.** Western blot of FtsX-GFP-His with anti-GFP antibody recovered in 1%  
56 (wt/vol) DDM-extracted membrane supernates from strain IU6892 (BL21AI/ pETCT *ftsX*-  
57 GFP-His) induced with different inducers. Lane 1, no inducer; lane 2, 0.001% (wt/vol)  
58 arabinose; lane 3, 0.01% (wt/vol) arabinose; lane 4, 0.02% arabinose (wt/vol); lane 5=  
59 0.05% (wt/vol) arabinose; lane 6, 0.1% (wt/vol) arabinose; lane 7, 0.5 mM IPTG; lane 8,  
60 0.5mM IPTG + 0.01% (wt/vol) arabinose. Maximal induction was observed in lane 8,  
61 which is the condition that produced maximal fluorescence intensity in DDM-extracted  
62 membrane supernates (see Table 1). The upper band is intact FtsX-GFP-His, whereas  
63 the lower bands present in all samples are degraded protein that retains the GFP  
64 epitope. Band intensities are not necessarily in the linear range of detection.


65 **Fig S2.** Growth curves of *E. coli* BL21DE3 cells expressing: no recombinant protein  
66 (blue diamond); FtsE-His from plasmid pET22b-*ftsE*-His (strain IU4340) (red squares);  
67 FtsX-His from plasmid pET22b-*ftsX*-His (strain IU6942) (green triangles); and FtsX-His  
68 and FtsE from plasmids pET22b-*ftsX*-His and pACYC Duet-*ftsE* (strain IU10589 (purple  
69 crosses). Strains are listed in Table S1. For growths, 50 mL of LB broth was inoculated  
70 with 50  $\mu$ L of overnight cultures of each strain and incubated with shaking at 25°C. At  
71  $OD_{600} = 0.5$ , recombinant proteins were induced with 1 mM IPTG (time = 0), and  $OD_{600}$   
72 was monitored with time. Data points are averages of three independent growths.  
73 Growth of strains expressing recombinant proteins slowed down significantly after  
74 induction, but the cultures did not lyse while expressed recombinant proteins.

75 **Fig. S3.** Fluorescence-detection size-exclusion chromatography (FSEC) to optimize  
76 the concentration of (A) detergents and (B) glycerol for FtsX-GFP-His purification.  
77 Besides the indicated detergents and glycerol, elution buffer contained 50 mM Tris-HCl  
78 pH 8.0, 200 mM NaCl, and columns were run at 0.5 mL per min. 15% (vol/vol) glycerol  
79 was added to the buffers in panel A. See Materials and Methods for additional details.

80 **Fig S4.** Western blot showing that FtsE-His runs at 30 kDa, instead of at 26 kDa on  
81 SDS-PAGE. FtsE-His was overexpressed in strain IU4340 (BL21DE3/pET22b-*ftsE*-His)  
82 that was induced for 20 h at 16°C following addition of 1 mM IPTG. FtsE-His was  
83 purified as described in Materials and Methods, and purified FtsE-His was analyzed by  
84 SDS-PAGE with Coomassie blue staining (left panel). Purified MBP-His was included as  
85 a positive control for detecting His-tagged proteins. The positions of standards from a  
86 size-standard ladder are indicated. The gel was then Western blotted as described in  
87 Materials and Methods (right panel). The Coomassie-stained gel shows that FtsE-His  
88 preparations contain at least two faint contaminant bands, and the Western blot show  
89 that the prominent 30 kDa band corresponds to FtsE-His.

90 **Fig. S5.** Association studies of purified FtsE-His and FtsX-His proteins using  
91 analytical size-exclusion chromatography (Superdex 200 30/100 column in 50 mM Tris-  
92 HCl pH 8.0, 200 mM NaCl, 5% (vol/vol) glycerol, 0.02% (wt/vol) DDM, 0.02% (wt vol)  
93 C<sub>12</sub>E<sub>8</sub>), performed as described in Materials and Methods. A. FtsE-His + FtsX-His (1:1  
94 molar ratio) B. FtsE-His + FtsX-His (1:1 molar ratio) + 5 mM ATP + 5 mM MgCl<sub>2</sub> + 0.5  
95 mM vanadate to allow trapping. FtsX-His alone (green, lines); FtsE-His alone (blue  
96 lines); mixtures of FtsE-His + FtsX-His (red lines). See text for additional details.





**Fig. S1**







Fig. S2

**A****B**



0.02% DDM(—),  
 0.05% DDM(—),  
 0.02% C12E8(—),  
 0.05% C12E8(—),  
 0.02% DDM + 0.02% C12E8(—)

0% glycerol, 0.02% DDM (—),  
 5% glycerol, 0.02% DDM (—),  
 10% glycerol, 0.02% DDM (—),  
 0% glycerol, 0.02% DDM + 0.02% C12E8 (—),  
 5% glycerol, 0.02% DDM + 0.02% C12E8 (—),  
 10% glycerol, 0.02% DDM + 0.02% C12E8 (—).

**Fig. S3**



**Fig. S4**



**Fig. S5**